Correlia Biosystems develops a proteomics platform. Their first commercial platform is for rapid detection of protein biomarkers providing high resolution and granular data from research, drug development, diagnostics, and personalized medicine.
History and Technology
The company was founded at UC Berkeley from 2 post-docs and a graduate student from the Herr Lab. The core technology they developed enabled rapid quantification of protein biomarker panels in under 15 min from only 2 microliters of sample.
Correlia launched in the inaugural class of the Foundry incubator at UC Berkeley. During this time they were able to secure grants from the NIH, NSF, and other sources totaling $875K which was used to develop the core technology for commercial use. In 2018, Correlia participated in the Y Combinator W2018 cohort to launch a seed fundraising round.
Documentaries, videos and podcasts
- Cluster: Synthetic biologyA cluster of topics related to synthetic biology.
- CancerDisease of cellular proliferation that is malignant and primary, characterized by uncontrolled cellular proliferation, local cell invasion and metastasis
- DiagnosisIdentification of the nature and cause of a certain phenomenon